Jonathan French, Sc.D.

Senior Science Advisor, Fellow II

Jonathan has over 10 years of drug development experience. He began his career as a project statistician; designing, analyzing and interpreting clinical trials in depression and ADHD. His primary areas of expertise range from model-based meta-analysis and applied Bayesian methods to modeling time-to-event data and missing data mechanisms.

Recent publications by this scientist

Variable or variate? A conundrum in pharmacometrics exposure–response models

February 22, 2023

Ana-Marija Grisic, Karthik Venkatakrishnan, Jonathan French, Akash Khandelwal. CPT Pharmacometrics Syst Pharmacol.  December, 20 2022. doi:10.1002/psp4.12905

View More

Disease Trajectory of SLE Clinical Endpoints and Covariates Affecting Disease Severity and Probability of Response: Analysis of Pooled Patient-Level Placebo (Standard-of-Care) Data to Enable Model-Informed Drug Development

November 17, 2022

Kosalaram Goteti, Jonathan French, Ramon Garcia, Ying Li, Florence Casset-Semanaz, Aida Aydemir, Robert Townsend, Cristina Vazquez Mateo, Matthew Studham, Oliver Guenther, Amy Kao, Marc Gastonguay, Pascal Girard, Lisa Benincosa, Karthik Venkatakrishnan. CPT Pharmacometrics Syst Pharmacol.  November, 9 2022. doi:10.1002/psp4.12888

View More

Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda

November 14, 2022

Katherine Kay, Justin Goodwin, Hanna Ehrlich, Joyce Ou, Tracey Freeman, Kaicheng Wang, Fangyong Li, Martina Wade, Jonathan French, Liusheng Huang, Francesca Aweeka, Norah Mwebaza, Richard Kajubi, Matthew Riggs, Ana Ruiz-Garcia, Sunil Parikh. Clin Pharmacol Ther. Published online October 19, 2022. doi:10.1002/cpt.2768

Download PDF

View More